About Rocket Pharmaceuticals Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.rocketpharma.com/
Frequently Asked Questions
What is the 52-week range for RCKT?
The 52-week high is $5.45 and the 52-week low is $2.51.
What is the P/E ratio for RCKT?
The P/E ratio data is currently unavailable.
What is the dividend yield for RCKT?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -5.76%.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 1.37.
Analyst Recommendation Trends
Wall Street analyst consensus for RCKT over the last few months:
Latest RCKT News
Rocket Pharmaceuticals (RCKT) Gets FDA Alignment on Heart Drug Trial. Can it Ease Safety Concerns?
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) said September 15 that the FDA agreed to count three patients treated under the modified RP-A501 protocol toward the pivotal Phase 2 efficacy cohort of 12 male patients. Nine additional patients remain to be enrolled and treated, with dosing expected to finish by mid-2027. Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) is developing RP-A501 […]
Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drug
Ultragenyx’s second gene therapy approval since August gives it another sellable voucher. Elsewhere, Roche declared success in a blood cancer trial and a cell therapy maker is cutting costs.
This JB Hunt Transport Analyst Turns Bullish; Here Are Top 4 Upgrades For Thursday
Analysts upgraded SUNB, HAWK, and more, revising ratings and price targets.
RCKT Aligns With FDA on Completing Phase II Study in Danon Disease
Rocket Pharmaceuticals aligns with the FDA on key phase II study elements for RP-A501, advancing its Danon disease gene therapy program toward completion.
Starbucks initiated, Expedia downgraded: Wall Street's top analyst calls
Starbucks initiated, Expedia downgraded: Wall Street's top analyst calls
Here Are Wednesday’s Top Wall Street Analyst Research Calls: Airbnb, Booking Holdings, Credicorp, Dutch Bros, Expedia, Hartford Financial Services, Group, Meritage Homes, Patchex, Yum! Brands, and More
Pre-Market Stock Futures: Futures are trading higher as the Federal Reserve’s reckoning day has arrived. Interest rate futures tracked by CME FedWatch show a 92% chance of a 25-basis-point increase in the Fed funds rate today. That will push the funds rate to 3.75% to 4%. In addition, market watchers expect two more rate hikes […]
Rocket Pharmaceuticals’ FDA Decision Clears ‘Meaningful Regulatory Overhang,’ Says Needham — Sees 150% Upside Potential In RCKT Stock
Needham said the FDA outcome was better than expected because the regulator could have demanded meaningful changes to Rocket’s Danon disease trial.
This Union Pacific Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
Analysts upgraded Similarweb, Rocket Pharmaceuticals, Radiant Logistics and Ulta Beauty; Paychex rose to Peer Perform, with targets raised.
Wedbush Reiterates Outperform on Rocket Pharmaceuticals, Maintains $15 Price Target
Wedbush analyst Yun Zhong reiterates Rocket Pharmaceuticals (NASDAQ:RCKT) with a Outperform and maintains $15 price target.
Needham Upgrades Rocket Pharmaceuticals to Buy, Announces $9 Price Target
Needham analyst Gil Blum upgrades Rocket Pharmaceuticals (NASDAQ:RCKT) from Hold to Buy and announces $9 price target.
Rocket Pharmaceuticals Shares Rise 8% After FDA Alignment on Danon Disease Trial
Rocket Pharmaceuticals (NASDAQ:RCKT) shares rose 8% on Tuesday after the company said it reached alignment with the US Food and Drug Administration on the pivotal Phase 2 trial of RP-A501 for Danon disease. The FDA confirmed a pivotal efficacy population of 12 patients, including the first three patients treated under the study’s modified protocol, according to Rocket.
Rocket Pharma Gets FDA Alignment On This Key Trial -- A Look At Some Key Highlights
The FDA confirmed continued enrollment and dosing under the modified trial protocol after reviewing safety data from the first three patients treated at the recalibrated dose.
Rocket Pharmaceuticals, Inc. (RCKT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Rocket Pharmaceuticals, Inc. (RCKT) Morgan Stanley 24th Annual Global Healthcare Conference September 15, 2026 9:15 AM EDTCompany ParticipantsGaurav Shah -...
Rocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon Disease
CRANBURY, N.J., September 15, 2026--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening diseases, focused on inherited cardiovascular disorders, today announced alignment with the U.S. Food and Drug Administration (FDA) on continued enrollment and dosing and key elements of the global pivotal Phase 2 trial of RP-A501 for the treatment of Danon disease, including the recalibrated dose, 12
Rocket Pharmaceuticals, Inc. (RCKT) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Rocket Pharmaceuticals, Inc. (RCKT) 12th Annual Cantor Fitzgerald Global Healthcare Conference September 10, 2026 1:00 PM EDTCompany ParticipantsGaurav Shah...
Rocket Pharmaceuticals Aligned With FDA on Continued Enrollment and Dosing and key elements of Phase 2 trial of RP-A501 for Danon disease
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening diseases, focused on inherited cardiovascular disorders,
Allogene Therapeutics (ALLO) Down 11.1% Since Last Earnings Report: Can It Rebound?
Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is AtaiBeckley Inc (ATAI) Up 0.8% Since Last Earnings Report?
AtaiBeckley Inc (ATAI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Rocket Pharmaceuticals (RCKT) Up 6% Since Last Earnings Report: Can It Continue?
Rocket Pharmaceuticals (RCKT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
CRANBURY, N.J., September 03, 2026--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare and devastating diseases, focused on inherited cardiovascular disorders, today announced that the Company will participate in the 2026 Cantor Global Healthcare Conference and the Morgan Stanley 24th Annual Global Healthcare Conference in New York.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-11 | Wilson Martin | -75,364 | $3.403 | $256,464 |
| 2026-08-18 | Wilson Martin | -631 | $3.381 | $2,133 |
| 2026-08-18 | Shah Gaurav | -2,293 | $3.381 | $7,753 |
| 2026-08-13 | Shah Gaurav | -2,837 | $3.381 | $9,592 |
| 2026-08-13 | Wilson Martin | -3,493 | $3.381 | $11,810 |
| 2026-08-11 | Stevens Christopher James | -36,658 | $3.499 | $128,266 |
| 2026-08-11 | Chaudhuri Sarbani | -4,701 | $3.499 | $16,449 |
| 2026-08-03 | Stevens Christopher James | +101,428 | - | - |
| 2026-08-03 | Stevens Christopher James | +73,313 | - | - |
| 2026-08-03 | SOUTHWELL DAVID P | +150,000 | - | - |
| 2026-06-18 | WONG RODERICK | +78,960 | - | - |
| 2026-06-18 | WONG RODERICK | +27,832 | - | - |
| 2026-06-18 | Fong Peter | +64,860 | - | - |
| 2026-06-18 | Fong Peter | +22,862 | - | - |
| 2026-06-18 | Dolsten Mikael | +64,860 | - | - |
| 2026-06-18 | Dolsten Mikael | +22,862 | - | - |
| 2026-06-18 | Malik Fady Ibraham | +64,860 | - | - |
| 2026-06-18 | Malik Fady Ibraham | +22,862 | - | - |
| 2026-06-18 | BOESS CARSTEN | +64,860 | - | - |
| 2026-06-18 | BOESS CARSTEN | +22,862 | - | - |
| 2026-06-18 | SOUTHWELL DAVID P | +64,860 | - | - |
| 2026-06-18 | SOUTHWELL DAVID P | +22,862 | - | - |
| 2026-05-26 | Militello John | +9,091 | - | - |
| 2026-05-26 | Militello John | +24,899 | - | - |
| 2026-05-26 | Militello John | +16,061 | - | - |
| 2026-05-26 | Militello John | +15,002 | - | - |
| 2026-05-26 | Militello John | +51,509 | - | - |
| 2026-05-26 | Militello John | -24,545 | - | - |
| 2026-05-26 | Militello John | -49,798 | - | - |
| 2026-05-26 | Militello John | -28,910 | - | - |
| 2026-05-26 | Militello John | -27,003 | - | - |
| 2026-05-26 | Militello John | -18,000 | - | - |
| 2026-05-26 | Militello John | -18,000 | - | - |
| 2026-05-26 | Militello John | -2,000 | - | - |
| 2026-05-26 | Militello John | -20,000 | - | - |
| 2026-05-26 | Militello John | -10,000 | - | - |
| 2026-05-26 | Militello John | -20,000 | - | - |
| 2026-05-26 | Militello John | -10,000 | - | - |
| 2026-05-26 | Militello John | -10,000 | - | - |
| 2026-05-21 | Shah Gaurav | -76,490 | $1.691 | $129,345 |
| 2026-05-21 | Shah Gaurav | -55,684 | $3.086 | $171,841 |
| 2026-05-21 | Shah Gaurav | +76,490 | $1.691 | $129,345 |
| 2026-05-19 | Shah Gaurav | -2,409 | $3.014 | $7,261 |
| 2026-05-19 | Wilson Martin | -662 | $3.014 | $1,995 |
| 2026-05-19 | Militello John | -384 | $3.014 | $1,157 |
| 2026-05-13 | Shah Gaurav | -2,728 | $3.606 | $9,837 |
| 2026-05-13 | Wilson Martin | -3,361 | $3.606 | $12,120 |
| 2026-05-13 | Militello John | -855 | $3.606 | $3,083 |
| 2026-05-07 | Chaudhuri Sarbani | -17,650 | $3.838 | $67,741 |
| 2026-02-18 | Militello John | -1,157 | $3.338 | $3,862 |
| 2026-02-18 | Shah Gaurav | -5,990 | $3.338 | $19,995 |
| 2026-02-18 | Wilson Martin | -1,376 | $3.338 | $4,593 |
| 2026-02-13 | Wilson Martin | -12,253 | $3.312 | $40,582 |
| 2026-02-13 | Militello John | -3,726 | $3.312 | $12,341 |
| 2026-02-13 | Shah Gaurav | -12,279 | $3.312 | $40,668 |
| 2026-02-11 | Shah Gaurav | +870,648 | - | - |
| 2026-02-11 | Shah Gaurav | +286,028 | - | - |
| 2026-02-11 | Militello John | +45,018 | - | - |
| 2026-02-11 | Militello John | +29,982 | - | - |
| 2026-02-11 | Wilson Martin | +468,187 | - | - |
| 2026-02-11 | Wilson Martin | +311,813 | - | - |
| 2026-02-11 | Rizvi Syed Ali-aamir | +93,037 | - | - |
| 2026-02-11 | Rizvi Syed Ali-aamir | +61,963 | - | - |
| 2026-02-11 | Stevens Christopher James | +93,037 | - | - |
| 2026-02-11 | Stevens Christopher James | +61,963 | - | - |
| 2026-02-11 | Chaudhuri Sarbani | +189,076 | - | - |
| 2026-02-11 | Chaudhuri Sarbani | +125,924 | - | - |
| 2026-01-02 | Bjork Elisabeth | +10,000 | $3.44 | $34,400 |
| 2025-11-18 | Militello John | -1,086 | $2.983 | $3,240 |
| 2025-11-18 | Schwartz Jonathan David | -2,545 | $2.983 | $7,592 |
| 2025-11-18 | Shah Gaurav | -6,276 | $2.983 | $18,721 |
| 2025-11-18 | Wilson Martin | -1,646 | $2.983 | $4,910 |
| 2025-11-03 | Wilson Martin | +100,000 | - | - |
| 2025-10-14 | Militello John | -558 | $3.975 | $2,218 |
| 2025-10-14 | Militello John | -3,005 | $3.97 | $11,930 |
| 2025-10-14 | Militello John | -5,514 | $3.965 | $21,863 |
| 2025-10-14 | Militello John | -19,841 | $3.96 | $78,570 |
| 2025-10-06 | Rizvi Syed Ali-aamir | +383,854 | - | - |
| 2025-10-06 | Rizvi Syed Ali-aamir | +62,893 | - | - |
| 2025-10-06 | Rizvi Syed Ali-aamir | +283,018 | - | - |